CAJ | 학술논문

目的：探讨NK细胞、CIK细胞及γδT细胞免疫治疗联合化疗治疗小细胞肺癌的临床疗效。方法选取94例小细胞肺癌患者为研究对象,根据其入院顺序分成联合组(A组,n=47)和对照组(B组,n=47)两组。 B组仅予以(依托泊苷+顺铂)单纯化疗方案，A组则采用细胞免疫联合化疗方案。行为期2~5年随访，比对两组患者总生存期及无进展生存期差异，记录其相关不良反应发生情况。结果①A、B两组的局限期患者在PFS及1年生存率对比上差异无统计学意义(P>0.05)；A组局限期患者OS及2年生存率优于B组(P<0.05)；A组广泛期患者在FPS、OS、1年及2年生存率等指标对比上均明显优于B组(P<0.05)；两组局限期患者PFS及OS均长于广泛期患者，差异有统计学意义(P<0.05)；②两组患者不良反应发生率对比差异无统计学意义(P>0.05)。结论对小细胞肺癌患者予以细胞免疫治疗联合化疗方案，疗效突出，值得临床推广。
목적：탐토NK세포、CIK세포급γδT세포면역치료연합화료치료소세포폐암적림상료효。방법선취94례소세포폐암환자위연구대상,근거기입원순서분성연합조(A조,n=47)화대조조(B조,n=47)량조。 B조부여이(의탁박감+순박)단순화료방안，A조칙채용세포면역연합화료방안。행위기2~5년수방，비대량조환자총생존기급무진전생존기차이，기록기상관불량반응발생정황。결과①A、B량조적국한기환자재PFS급1년생존솔대비상차이무통계학의의(P>0.05)；A조국한기환자OS급2년생존솔우우B조(P<0.05)；A조엄범기환자재FPS、OS、1년급2년생존솔등지표대비상균명현우우B조(P<0.05)；량조국한기환자PFS급OS균장우엄범기환자，차이유통계학의의(P<0.05)；②량조환자불량반응발생솔대비차이무통계학의의(P>0.05)。결론대소세포폐암환자여이세포면역치료연합화료방안，료효돌출，치득림상추엄。
Objective To investigate the clinical efficacy of NK cells, CIK cells and T cells immunotherapy combined with chemotherapy in the treatment of small cell lung cancer. Methods 94 patients with small cell lung cancer were selected as the re-search objects and divided into combined group (group A, n=47) and control group (group B, n=47) according to the admission time.Group B was received only chemotherapy scheme (etoposide +cisplatin), while group A was treated with combined cells im-munotherapy. In the 2-5 years following-up, overall survival and progression free survival were compared between the two groups and occurrence of adverse reactions of them were recorded. Results ①The PFS and 1 years survival rate of group A.B at limited stage had no statistic significance (P>0.05);Limited stage of patients in group A with OS and 2 years survival rate was better than that of group B (P<0.05);Contrast to FPS, wide OS, 1 years and 2 years survival rate and other indicators in group A during ex-tensive stage were obviously better than those in B group (P<0.05);the PFS and OS in two group of limited stage of patients were longer than those of patients , differences were significant (P<0.05); ② The toxic side effect reaction rate of two groups patients had no significant (P>0.05). Conclusion For patients with small cell lung cancer, the curative effect of cells immunotherapy com-bined with chemotherapy is obvious, so it is worth the clinical promotion.